Meyka Pro banner
Gelteq Limited Ordinary Shares

Gelteq Limited Ordinary Shares Fundamental Analysis

GELSNASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$0.61
$0.009(1.47%)
U.S. Market is Open · 15:42

Gelteq Limited Ordinary Shares Fundamental Analysis

Gelteq Limited Ordinary Shares (GELS) shows weak financial fundamentals with a PE ratio of -2.31, profit margin of -20.95%, and ROE of -24.94%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.02

Areas of Concern

ROE-24.94%
Operating Margin-19.86%
Cash Position0.15%
Current Ratio0.09
We analyze GELS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1974.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1974.5/100

We analyze GELS's fundamental strength across five key dimensions:

Efficiency Score

Weak

GELS struggles to generate sufficient returns from assets.

ROA > 10%
-18.59%

Valuation Score

Excellent

GELS trades at attractive valuation levels.

PE < 25
-2.31
PEG Ratio < 2
-0.02

Growth Score

Weak

GELS faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

GELS shows balanced financial health with some risks.

Debt/Equity < 1
0.36
Current Ratio > 1
0.09

Profitability Score

Weak

GELS struggles to sustain strong margins.

ROE > 15%
-2494.23%
Net Margin ≥ 15%
-20.95%
Positive Free Cash Flow
No

Key Financial Metrics

Is GELS Expensive or Cheap?

P/E Ratio

GELS trades at -2.31 times earnings. This suggests potential undervaluation.

-2.31

PEG Ratio

When adjusting for growth, GELS's PEG of -0.02 indicates potential undervaluation.

-0.02

Price to Book

The market values Gelteq Limited Ordinary Shares at 0.61 times its book value. This may indicate undervaluation.

0.61

EV/EBITDA

Enterprise value stands at -0.86 times EBITDA. This is generally considered low.

-0.86

How Well Does GELS Make Money?

Net Profit Margin

For every $100 in sales, Gelteq Limited Ordinary Shares keeps $-20.95 as profit after all expenses.

-20.95%

Operating Margin

Core operations generate -19.86 in profit for every $100 in revenue, before interest and taxes.

-19.86%

ROE

Management delivers $-24.94 in profit for every $100 of shareholder equity.

-24.94%

ROA

Gelteq Limited Ordinary Shares generates $-18.59 in profit for every $100 in assets, demonstrating efficient asset deployment.

-18.59%

Following the Money - Real Cash Generation

Operating Cash Flow

Gelteq Limited Ordinary Shares generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.

$0.00

Free Cash Flow

Gelteq Limited Ordinary Shares generates weak or negative free cash flow of $0.00, restricting financial flexibility.

$0.00

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

FCF Yield

GELS converts 0.00% of its market value into free cash.

0.00%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.31

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.02

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.61

vs 25 benchmark

P/S Ratio

Price to sales ratio

42.74

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.36

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.09

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.25

vs 25 benchmark

ROA

Return on assets percentage

-0.19

vs 25 benchmark

ROCE

Return on capital employed

-0.25

vs 25 benchmark

How GELS Stacks Against Its Sector Peers

MetricGELS ValueSector AveragePerformance
P/E Ratio-2.3129.33 Better (Cheaper)
ROE-24.94%426.00% Weak
Net Margin-2095.34%-11441.00% (disorted) Weak
Debt/Equity0.360.78 Strong (Low Leverage)
Current Ratio0.095.12 Weak Liquidity
ROA-18.59%-120.00% (disorted) Weak

GELS outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Gelteq Limited Ordinary Shares's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ